Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NTP and ephedra

This article was originally published in The Tan Sheet

Executive Summary

National Toxicology Program's Board of Scientific Counselors will consider comments and data on toxicology of ephedrine alkaloid dietary supplements Sept. 18 in Research Triangle Park, N.C., according to an 1Aug. 19 Federal Register notice. In June, an NTP committee recommended that ephedrine alkaloid supplements undergo various toxicological studies and requested public feedback by Aug. 12 2("The Tan Sheet" July 1, 2002, p. 20). In comments, Bradenton, Fla.-based Med-Tox Group cautions NTP testing of ephedrine alkaloids "may be compromised by the true identity of the substance tested, and its relevance to commercial products." Separately, a U.S. Army Forces Command senior physician assistant notes ephedra products still are sold on military bases "in part due to a lack of 'scientific study' and proof that they are in fact hazardous when used in high physical stress and high temperature environments"...

You may also be interested in...



NTP Ephedrine Alkaloid Toxicity Studies Under Review

The National Toxicology Program is asking for toxicology data on ephedrine alkaloid dietary supplements by Aug. 12

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094457

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel